CSV leads in funeral business margins: Can its valuation discount narrow?

Analysis

The OP argues that U.S. funeral services operator Carriage Services (CSV) is mispriced relative to industry leader Service Corporation International (SCI): it has higher profitability and similar leverage, yet trades at substantially lower multiples. CSV operates 155 funeral homes and 28 cemeteries; the OP attributes its share price decline of approximately 35% from its April high to two consecutive quarters of earnings misses and weak death volumes. The supporting argument is that second-quarter at-need volume declined 3.5%, but when the company lowered revenue guidance to $435 million–$445 million, it maintained its adjusted EBITDA, EPS, and free cash flow guidance, suggesting that pricing, preneed sales, and cost controls can cushion demand pressure. The official release supports these operating figures, but full-year guidance is not yet realized profit. (investors.carriageservices.com) The OP cites the Census Bureau's 2018 projections, viewing the aging of baby boomers as support for long-term demand, and explains weakness in 2026 as the pandemic having pulled forward deaths. The former has a source, while the latter lacks direct evidence; long-term growth in deaths also does not guarantee proportional growth for CSV. (census.gov) The margin comparison emphasizes CSV's first-half gross margin of 35.2%, operating margin of 23.5%, and adjusted net margin of 12.6%, along with its second-quarter financial business EBITDA margin of 93.2%, 21.1% growth in insurance-funded preneed contracts, and a 17.9% increase in the average price of comparable cemetery interment rights. However, the financial segment's high margin cannot be equated with a profitability advantage across the entire sales chain, and cemetery price increases were accompanied by declining comparable sales volume, so they do not directly establish an expanding backlog. (investors.carriageservices.com) The valuation uses the October 8, 2026 closing price of $33.73 listed by the OP, a market capitalization of approximately $536 million, and net debt of approximately $537 million. Using the midpoint of CSV's full-year guidance yields 7.8x EV/EBITDA and a 9.8x price-to-earnings ratio; for SCI, the OP independently reconstructs and annualizes first-half EBITDA to obtain 11.8x and 18.3x, so the approximately 34% discount is not based on fully comparable periods and methodologies. Using approximately 15.9 million shares, the OP calculates that multiples rising to 9.5x, 10x, and 11.8x would imply prices of approximately $48, $53, and $68, respectively, while a decline to 6.5x would imply approximately $22. These are scenario values under fixed debt and earnings assumptions, not independently established price targets. The OP reports holding 330 shares at a cost basis of $44.83 and cites an unverified average analyst target of $61.67; there are no attached images or position screenshots. Catalysts include a recovery in death-related demand, acquisitions over the next several quarters, and third-quarter results in early November, inferred from the usual reporting schedule; an SCI acquisition of CSV is explicitly only speculation. The core assumptions are that weak volume is temporary, pricing and financial revenue are sustainable, and acquisitions can spread corporate overhead across a larger revenue base without materially increasing debt or the share count. The biggest weaknesses are equating similar leverage multiples with similar risk and treating acquisition accretion as almost automatic; CSV's weak cash conversion, financing risk, and dilution risk may reasonably explain the discount. SCI's cash flow is also affected by tax credits and related investment outlays, requiring a consistent comparison methodology. (news.sci-corp.com) Other risks acknowledged by the OP include floating-rate debt, low liquidity, potential market share losses, and substitution toward cremation; SCI is primarily used as a benchmark rather than presented as a standalone investment thesis.

Discussion Summary

There are 10 comments in total, with too few substantive contributions to draw conclusions. The highest-scoring comment questions whether the content was AI-generated and requests proof of the position, while another thread says the moderators have been notified. Although the post reports a holding, there is no screenshot and no response from the OP. The only relatively substantive view is that small-cap companies are more prone to mispricing, but it does not verify CSV's figures. A small amount of support merely expresses interest and does not establish a meaningful consensus on valuation or cash flow.

Fact Check

• supported: CSV's second-quarter at-need volume declined 3.5%, and it lowered revenue guidance while maintaining EBITDA, EPS, and free cash flow guidance. — The company's August 5, 2026 release confirms revenue guidance of $435 million–$445 million, adjusted EBITDA of $135 million–$140 million, EPS of $3.35–$3.55, and free cash flow of $40 million–$50 million. Maintaining guidance does not mean full-year profits have already been realized.
• questionable: CSV's financial business EBITDA margin of 93.2% and 17.9% increase in the average price of comparable cemetery interment rights prove that its preneed backlog is expanding. — Both percentages are supported by the release, but comparable preneed cemetery interment rights sold declined from 3997 to 3316, a decrease of approximately 17%; sales value increased only approximately 1.4%. Higher prices do not mean a larger backlog by volume, and a segment margin does not represent the margin across the entire sales chain.
• questionable: CSV's overall margins are higher than SCI's, so the valuation gap lacks a reasonable basis. — The first-half comparisons of operating margins of approximately 23.5% versus 21.6% and adjusted net margins of approximately 12.6% versus 11.8% hold up. However, the OP also acknowledges weaknesses in CSV's corporate overhead and cash conversion; additionally, directly comparing CSV's segment EBITDA margins with SCI's segment gross margins does not establish an advantage on a like-for-like basis.
• questionable: Both companies have net debt/EBITDA of approximately 3.9x, so their debt risk is essentially the same. — CSV's net debt, including finance leases, is approximately $537 million; SCI's balance-sheet debt less cash is approximately $5.043 billion, close to the figure in the post. However, CSV uses full-year guidance while SCI uses a reconstructed, annualized first-half figure, and similar multiples do not eliminate differences in financing structure, cash conversion, and scale. CSV's release reports bank leverage of 4.0x.
• questionable: SCI's EBITDA cash conversion rate of approximately 53% is substantially ahead of CSV's approximately 33%. — For CSV, dividing the $45 million midpoint of free cash flow guidance by $137.5 million of EBITDA yields approximately 32.7%, so the arithmetic holds up. SCI's midpoint for adjusted operating cash flow after taxes is $1.085 billion, with maintenance capital expenditures of $335 million, but growth expenditures are estimated by the author; investments related to tax credits also involve $40.7 million in cash outflows, and excluding them would overstate cash conversion in economic terms.
• supported: The Census Bureau projects that all baby boomers will be older than 65 by 2030, older adults will outnumber minors by 2034, and deaths will increase over the long term. — The post accurately summarizes the projections released in 2018: 77 million people aged 65 and older versus 76.5 million minors in 2034, with deaths projected to increase substantially over 2020–2050. These are older projections, not the latest projections as of 2026, and they do not directly establish that near-term business volume will rebound. ([census.gov](https://census.gov/newsroom/press-releases/2018/cb18-41-population-projections.html))
• unsupported: Weak death-related demand in 2026 primarily reflects COVID having pulled forward deaths, and demand will subsequently revert to the mean. — CSV's release only notes weak national death trends and encouraging trends in July. It does not provide causal evidence that pandemic-related pull-forward effects caused weakness in 2026, nor does it guarantee near-term mean reversion.
• supported: Revaluing CSV at 9.5–11.8x EBITDA implies a share price of approximately $48–$68. — Checking only the assumptions given in the post: using $137.5 million of EBITDA, $537 million of net debt, and 15.9 million shares, 9.5x implies approximately $48.38 and 11.8x approximately $68.27. The arithmetic holds up, but the appropriateness of the multiples and future changes in debt and share count have not been verified; this item does not confirm the October 8 market price.
• unsupported: An SCI acquisition of CSV at 10x EBITDA would be immediately earnings-accretive. — Acquisition accretion also depends on financing costs, synergies, taxes, transaction expenses, and acquisition accounting; it cannot be inferred solely from the two companies' trading multiples. The post also provides no evidence of ongoing acquisition talks.